Loading…
Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration
Even though hemodialysis is a renal replacement therapy that allows patients with end-stage renal disease to be kept alive, cardiovascular morbidity and mortality are very high. The dialysis membrane where the exchange of uremic toxins between the blood and the dialysis fluid occurs is the key eleme...
Saved in:
Published in: | Clinical Kidney Journal 2023, Vol.16 (11), p.2254 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Report |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Even though hemodialysis is a renal replacement therapy that allows patients with end-stage renal disease to be kept alive, cardiovascular morbidity and mortality are very high. The dialysis membrane where the exchange of uremic toxins between the blood and the dialysis fluid occurs is the key element of the hemodialysis procedure. A new generation of membranes, called medium cut-off because they allow the removal of a greater number of medium-sized molecules, have generated a new concept of therapy called expanded HD. The objective of this study is to compare this new therapy with the technique that up to now has shown superiority in terms of survival, online hemodiafiltration. |
---|---|
ISSN: | 2048-8505 |
DOI: | 10.1093/ckj/sfad128 |